ST. LOUIS, May 2 /PRNewswire-FirstCall/ -- GenoMed , a Next Generation Disease Management company whose business is public health(TM), announced today that Missouri State Representative Jeanette Mott Oxford has offered her congratulations to GenoMed on its novel treatment for chronic kidney failure.
GenoMed was the first to prove that chronic kidney failure may not be so chronic after all, at least early in its course. GenoMed's CEO, David Moskowitz MD, showed that chronic kidney failure due to diabetes or high blood pressure can actually be reversed early in the course of the disease.
Said the Honorable Ms. Mott Oxford, Representative for Missouri's 59th House District, "Prevention of dialysis will save federal dollars and allow a much better quality of life for Missourians. The State of Missouri will benefit from healthier, more productive people who can continue to help others, rather than be a burden themselves."
Rep. Mott Oxford continued, "I am particularly excited by the implication this has for our state Medicaid budget. If kidney disease from diabetes and high blood pressure can be controlled, then maybe heart disease and other complications can be, too. If so, the cost of cardiovascular disease could finally be reduced in Missouri."
Rep. Mott Oxford added, "Dr. Moskowitz came to my attention a few years ago when he fought for a friend of mine with emphysema to receive proper treatment in a system that wanted to deny him needed medicines. As time has passed, my admiration has only grown."
Dr. Moskowitz was recently presented with the 2006 Defender of Patient Safety Award (physician category) by Missouri Watch ( http://www.missouriwatch.net ). His results were published in Diabetes Technology and Therapeutics, a peer-reviewed medical journal, in September, 2002. If applied nationally, Dr. Moskowitz's method could prevent up to 90% of dialysis, and save Medicare over $22 billion a year. GenoMed owns the patents pending for this novel treatment approach.
About GenoMed
GenoMed uses genomics to help medicine(TM). The company's primary commitment is to public health, including education. http://www.genomed.com
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
GenoMedCONTACT: David W. Moskowitz MD, CEO, GenoMed, +1-314-983-9938,dwmoskowitz@genomed.com
